Selegiline Hydrochloride Capsule
Product Images NDC 16571-659

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Selegiline Hydrochloride (NDC 16571-659). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

500ct

500ct
This appears to be a label of medication called Selegiline Hydrochloride, which comes in a bottle with 500 capsules. The manufacturer could be "Rising" and the product may comply with the United States Pharmacopeia.*
FDA Label Image

60ct

60ct
FDA Label Image

Chemical Structure (Chemstructure)

Chemical Structure (Chemstructure)
FDA Label Image

Adverse Reactions Table (Table Adverse Events V2)

Adverse Reactions Table (Table Adverse Events V2)
This text provides a table that shows the incidence of adverse events in a clinical trial that was placebo-controlled. The trial evaluated the effect of selegiline hydrochloride in a group of 50 patients versus placebo in a group of 49 patients. The table shows the number of patients reporting each adverse event. The adverse events reported in the selegiline hydrochloride group include nausea, dizziness/light-headed/fainting, abdominal pain, confusion, hallucinations, dry mouth, dyskinesias, headache, and vivid dreams. The placebo group reported aches, anxiety/tension, anemia, diarrhea, hair loss, insomnia, leg pain, low back pain, malaise, palpitations, urinary retention, lethargy, and weight loss.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.